Clinical pharmacy services in hematology can have a significant impact, and the Pharmacy Times® Hematology resource center provides clinical news and articles about the topic. Here, visitors will find information about upcoming hematology conferences and meetings, updated clinical trial listings, and other resources.
The FDA granted fast track designation to the investigational CD20-directed monoclonal antibody ublituximab in combination with the PI3K-delta inhibitor umbralisib for the treatment of chronic lymphocytic leukemia.
The FDA action was based on results from the Phase 3 CheckMate -9ER trial evaluating nivolumab in combination with cabozantinib compared with sunitinib among patients with previously untreated advanced RCC.
Copanlisib (Aliqopa) in combination with rituximab (Rituxan) prolonged progression-free survival in patients with non-Hodgkin lymphoma who relapsed following 1 or more previous lines of rituximab-based therapy.
KG is a female patient aged 44 years who came to the pharmacy with a prescription that the pharmacist recognized is the treatment regimen for a new blood clot.
The Pharmacy Times® Hematology specialty page serves as a hub for all clinical news and articles related to hematological conditions. The coverage includes updates from the floor of all the biggest societal conferences and annual meetings, like the American Society of Hematology Annual Meeting, as well as video interviews of the leading hematologists and key opinion leaders in the space.